Chinese authorities have given conditional approval for general public use of a coronavirus vaccine developed by state-owned drugmaker Sinopharm.
The move came a day after the firm said interim data showed its leading vaccine had a 79% efficacy rate in phase three trials, without providing more details.
Several Chinese-made vaccines at a late trial stage are already in use in China after being granted emergency licences.
The pandemic emerged in the central Chinese city of Wuhan in December 2019.
It has since spread around the world, but China has managed to bring infection rates down to very low levels through strict anti-virus measures.
The search for the source of the coronavirus has led to tensions with the West. The US – among a number of other countries – raised questions about whether China was fully transparent when the virus first emerged there.
Thursday’s announcement concerning the vaccine made by the China National Pharmaceutical Group, or Sinopharm, is China’s first general approval of a homemade jab – and it is being seen as potentially a major step towards inoculating the world’s largest population.
